RPRX Stock Overview
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 1/6 |
Rewards
Risk Analysis
+ 1 more risk
Royalty Pharma plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$26.61 |
52 Week High | US$44.47 |
52 Week Low | US$25.92 |
Beta | 0.40 |
1 Month Change | -11.92% |
3 Month Change | -10.82% |
1 Year Change | -33.27% |
3 Year Change | -35.43% |
5 Year Change | n/a |
Change since IPO | -40.20% |
Recent News & Updates
Recent updates
Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's
May 12Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20
Apr 20Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20
Jan 16Royalty Pharma to co-fund development of schizophrenia drug with Merck
Oct 12Royalty Pharma: Strategic Royalty Interest Acquisition To Drive Significant Growth
Aug 18Royalty Pharma declares $0.19 dividend
Jul 15Royalty Pharma: Unique Diversification, Bear Market Performer
May 26The Price Is Right For Royalty Pharma plc (NASDAQ:RPRX)
Apr 25Royalty Pharma Offers A Unique Long-Term Investment Opportunity
Mar 01Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To US$0.19
Jan 25Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At US$0.19
Jan 11Royalty Pharma: A Pharma-Like Company Without The Same Risks
Dec 27Royalty Pharma Provides Unique Diversity To A Biopharma Portfolio
Oct 27Royalty Pharma (RPRX) MorphoSys Transaction Call
Jun 11Royalty Pharma: A Potentially Long-Term Dividend Investment
May 04Key Things To Watch Out For If You Are After Royalty Pharma plc's (NASDAQ:RPRX) 1.6% Dividend
Mar 08Do Insiders Own Lots Of Shares In Royalty Pharma plc (NASDAQ:RPRX)?
Feb 01Royalty Pharma raises dividend by 13% to $0.17 per share
Jan 08Shareholder Returns
RPRX | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -4.9% | -2.0% | -2.7% |
1Y | -33.3% | 11.9% | 16.8% |
Return vs Industry: RPRX underperformed the US Pharmaceuticals industry which returned 10.8% over the past year.
Return vs Market: RPRX underperformed the US Market which returned 15.1% over the past year.
Price Volatility
RPRX volatility | |
---|---|
RPRX Average Weekly Movement | 2.8% |
Pharmaceuticals Industry Average Movement | 9.5% |
Market Average Movement | 5.5% |
10% most volatile stocks in US Market | 14.2% |
10% least volatile stocks in US Market | 2.5% |
Stable Share Price: RPRX is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: RPRX's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1996 | n/a | Pablo Legorreta | https://www.royaltypharma.com |
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Royalty Pharma plc Fundamentals Summary
RPRX fundamental statistics | |
---|---|
Market Cap | US$15.97b |
Earnings (TTM) | US$254.95m |
Revenue (TTM) | US$2.36b |
46.9x
P/E Ratio5.1x
P/S RatioIs RPRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RPRX income statement (TTM) | |
---|---|
Revenue | US$2.36b |
Cost of Revenue | US$973.94m |
Gross Profit | US$1.39b |
Other Expenses | US$1.13b |
Earnings | US$254.95m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.57 |
Gross Margin | 58.76% |
Net Profit Margin | 10.80% |
Debt/Equity Ratio | 72.6% |
How did RPRX perform over the long term?
See historical performance and comparison